Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1995-11-21
1998-06-30
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514824, A61K 31135
Patent
active
057734798
ABSTRACT:
TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation of vascular smooth muscle cells over time. Further provided is a method for upregulating cellular mRNA coding for TGF-beta.
REFERENCES:
patent: 2914563 (1959-11-01), Allen et al.
patent: 3010965 (1961-11-01), Elpern
patent: 3168565 (1965-02-01), Palopoli et al.
patent: 3288806 (1966-11-01), DeWald et al.
patent: 3634517 (1972-01-01), Palopoli et al.
patent: 4133814 (1979-01-01), Jones et al.
patent: 4230862 (1980-10-01), Suarez et al.
patent: 4235988 (1980-11-01), Fildes et al.
patent: 4307111 (1981-12-01), Crawley
patent: 4418068 (1983-11-01), Jones
patent: 4442119 (1984-04-01), Magarian et al.
patent: 4536516 (1985-08-01), Harper et al.
patent: 4696949 (1987-09-01), Toivola et al.
patent: 4824436 (1989-04-01), Wolinsky
patent: 4826672 (1989-05-01), Milius et al.
patent: 4839155 (1989-06-01), Mccague
patent: 4859585 (1989-08-01), Sonnenschein et al.
patent: 4879315 (1989-11-01), Magarian et al.
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 4973755 (1990-11-01), Grafe et al.
patent: 4990538 (1991-02-01), Harris et al.
patent: 4996225 (1991-02-01), Toivola et al.
patent: 4997652 (1991-03-01), Wong
patent: 5015666 (1991-05-01), Magarian et al.
patent: 5032679 (1991-07-01), Brandley et al.
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5098903 (1992-03-01), Magarian et al.
patent: 5112305 (1992-05-01), Barath et al.
patent: 5120535 (1992-06-01), Marquardt et al.
patent: 5140012 (1992-08-01), McGovern et al.
patent: 5166143 (1992-11-01), Ondetti et al.
patent: 5171217 (1992-12-01), March et al.
patent: 5189046 (1993-02-01), Burch et al.
patent: 5189212 (1993-02-01), Ruenitz
patent: 5192525 (1993-03-01), Yang et al.
patent: 5208019 (1993-05-01), Hanson et al.
patent: 5216024 (1993-06-01), Markaverich et al.
patent: 5219548 (1993-06-01), Yang et al.
patent: 5221620 (1993-06-01), Purchio et al.
patent: 5238950 (1993-08-01), Clader et al.
patent: 5254594 (1993-10-01), Niikura et al.
patent: 5268358 (1993-12-01), Fretto
patent: 5270047 (1993-12-01), Kauffman et al.
patent: 5280016 (1994-01-01), Conrad et al.
patent: 5280109 (1994-01-01), Miyazono et al.
patent: 5283257 (1994-02-01), Gregory et al.
patent: 5284763 (1994-02-01), Derynk et al.
patent: 5288711 (1994-02-01), Mitchell et al.
patent: 5304541 (1994-04-01), Purchio et al.
patent: 5308622 (1994-05-01), Casscells et al.
patent: 5308862 (1994-05-01), Ohlstein
patent: 5324736 (1994-06-01), Magarin et al.
patent: 5326757 (1994-07-01), Demopoulos
patent: 5362424 (1994-11-01), Lee et al.
patent: 5393763 (1995-02-01), Black et al.
patent: 5393785 (1995-02-01), Labrie et al.
patent: 5395842 (1995-03-01), Labrie et al.
patent: 5453436 (1995-09-01), Ohlstein
patent: 5468746 (1995-11-01), Casagrande et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5491173 (1996-02-01), Toivola et al.
Chao, C. C., et al., "Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome", Cytokine, 3, 292-298 (Jul., 1991).
Fischer, G. M., et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis," Exp. Molec. Pathol., 43, 288-296 (1985).
Marzocchi, A., et al., translation of "Restenosis After Coronary Angioplasty: Its Pathogenesis and Prevention", Cardiologia, 36, 309-320 (Dec., 1991).
Wakefield, L. M., et al., "Recombinant Latent Transforming Growth Factor .beta.1 Has a Longer Plasma Half-Life in Rats than Active Transforming Growth Factor .beta.1, and a Different Tissue Distribution", J. Clin. Invest., 86, 1976-1984 (Dec., 1990).
Weissberg, P. L., et al., "Is Vascular Smooth Muscle Cell Proliferation Beneficial?" Lancet, 347, 305-307 (Feb., 1996).
Assoian, et al., "Type Beta Transforming Growth Factor in Human Platelets: Release Duringn Platelet Degranulation and Action of Vascular Smooth Muscle Cells", J. Cell Biol, 102, 1217-1223 (Apr. 1986).
Bagdade, et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition", J. Clinical Endocrinology and Metabolism, 70, 1132-1135 (1990).
Barath, et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury", JACC, 13, 252A (Feb. 1989).
Bertelli, et al., "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antithrombin III Levels", Breast Cancer Res. and Treatment, 12, 307-310 (1988).
Bruengger, et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steriod Induced Hyperplasia and Estrogen or Mamoxifen Treated Dogs", J. Urology, 130, 1208-1210 (Dec. 1983).
Bruning, et al., "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", Br. J. Cancer, 58, 497-499 (1988).
Butta, et al., "Inductioin of Transforming Growth Factor B1 in Human Breast Cancer in Vivo Following Tamoxifen Treatment", Cancer Res., 52, 4261-4264 (Aug. 1, 1992).
Chander, et al., "Pyrrolidino-4-idotamoxifen and 4-idotamamoxifen New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer", Cancer Res., 51, 5851-5858 (Nov. 1, 1991).
Craig, et al., In: Modern Pharmacology, Little Brown and Company, p. 399 (1982).
Crissman, et al., "Transformed mammalian cells are deficient in kinase-mediated control of progression through the Gl phase of the cell cycle", Proc. Natl. Acad. Sci. USA, 88, 7580-84 (Sep., 1991).
Dimond, et al., "TGF-Beta Shows Potetial as Theapeutic Agent for Macular Holes", Genetic Eng. News, 7, 19 (Feb. 1, 1993).
Fanelli, et al., "Restenosis Following Coronary Angioplasty", Amer. Heart J., 119, 357-368 (Feb. 1990).
Farhat, et al., "In Vitro Effect of Oestradiol on Thymidine Uptake in Pulmonary Vascular Smooth Muscle Cell: Role of the Endothelium", Br. J. Pharmacol., 107, 679-683 (1992).
Fischer, et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atheroslcerosis, Experimental and Molecular Pathology.", Exp. Mol. Patho., 43, 288-296 (1985).
Forrester, et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies", JACC, 17, 758-769 (Mar. 1, 1991).
Grainger, et al., "Proliferation of Human Smooth Muscle Cells Promoted by lipoprotein (a)," Scence, 260, 1655-58 (Jun., 1993).
Grainger, et al., "Tamoxifen Decreases the Rate of Proliferation of Rat Vascular Smooth-Muscle Cells in Culture by Inducing Production of Transforming Growth Factor beta", Biochem. J., 294, 109-112 (1993).
Grainger, et al., "Effect of Tamoxifen in the Rate Carotid Injury Model In Vivo", Manuscript in Preparation, (1996).
Grainger, et al., "Hexamthylenebiascetamide Selectively Inhibits the Proliferation of Human and Rat Vascular Smooth-Muscle Cells", Biochem J., 282, 403-408 (1992).
Hanke, et al., "Inhibition of Cellular Proleration After Experimental Balloon Angioplastic by Low-Molecular-Weight Heparin", Circulation, 85, 1548-1556 (Apr. 1992).
Harpel, et al., "Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin," Proc. Natl. Acad. Sci. USA, 86, 3847-3851 (1989).
Henriksson, et al., "Hormonal Regulation of Serum Lp (a) Levels," J. Clin. Invest., 89, 1166-1171 (Apr., 1992).
Hofmann, et al., "Enchancement of the Antiproliferation Effect of cis-Diamminedichloroplatinum(II) and Nitrogen Mustard by Inihibitors of Protein Kinase C", Int. J. Cancer, 42, 382-388 (1988).
Hwang, et al., "Effects of Platelet-Contained Growth Factors (PDGF, EGF, IGF-1, and TGF-B) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture.", Exp. Cell Res., 200, 358-360, (1992).
Jande, et al., "Effects of cytoc
Grainger David J.
Metcalfe James C.
Weissberg Peter L.
Henley III Raymond
NeoRx Corporation
LandOfFree
Prevention and treatment of pathologies associated with abnormal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of pathologies associated with abnormal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of pathologies associated with abnormal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1859868